samedan logo
 
 
spacer
home > pmps > summer 2019 > planning your automation project
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Planning Your Automation Project

At the end of 2018, the Medicines and Healthcare products Regulatory Agency undertook a pharmacy-level recall of several batches of blood pressure and heart medication (valsartancontaining medicines) made by Mylan and Teva. This followed previous action across Europe recalling the same substance from Dexcel and Actavis. The precautionary measure was put in place to prevent any risk to patient safety after an impurity was identified as part of the manufacturing process.

When the stakes of manufacturing are so high, it is only natural to want to stick with tried and tested methods. Any issues that occur during the manufacturing process can have a significant impact on drug supply and patient care; for example, patients cannot just stop taking their blood pressure and heart medication.

However, incorporating automation equipment and software into the production line can lead to myriad benefits. A more robust, modern manufacturing approach can lead to fewer interruptions, fewer product failures, and greater confidence that drugs will meet clinical performance. While industries like automotive and aerospace have excelled in automation, many pharmaceutical companies are concerned that the technology is too complex a change.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marketing Director by day, Jonathan Wilkins is also one of the most prolific Industry 4.0 writers in the industrial automation sector. A professional brand advocate and commercial marketing strategist, Jonathan has been part of the EU Automation team since its humble beginnings in 2009 and has over a decade of experience in marketing.
spacer
Jonathan Wilkins
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution

October 5th, 2021 SCHLIEREN, (Zurich, Switzerland). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, today announces the upcoming launch of its next-generation plasma biomarker discovery solution.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement